AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26232126 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic milk containing Lactobacillus rhamnosos GG, L. acidophilus La‐5, and Bifidobacterium animalis subsp. lactis Bb‐12
Number of subjects: 415
Study 26232126 — intervention group
Group type: COMPARATOR
Intervention: Placebo milk
Number of subjects: 415
Study 24023537 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant mental health intervention
Number of subjects: 0
Study 24023537 — intervention group
Group type: COMPARATOR
Intervention: Enhanced service as usual
Number of subjects: 0
Study 20643863 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin plus pegylated liposomal doxorubicin (PLD)
Number of subjects: 672
Study 20643863 — intervention group
Group type: COMPARATOR
Intervention: Single-agent PLD
Number of subjects: 672
Study 19629666 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation for atrial fibrillation (AF) - pulmonary veins antrum isolation (PVAI)
Number of subjects: 29
Study 17432401 — intervention group
Group type: COMPARATOR
Intervention: Control group (flowable and microhybrid resin composites)
Number of subjects: 80
Study 17432401 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 7 (flowable A + microhybrid resin A + post A)
Number of subjects: 80
Study 17432401 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 8 (flowable B + microhybrid resin B + post B)
Number of subjects: 80
Study 17432401 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 6 (flowable B + microhybrid resin B)
Number of subjects: 80
Study 17432401 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5 (microhybrid resin B)
Number of subjects: 80
Study 17432401 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (microhybrid resin A)
Number of subjects: 80
Study 17432401 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (flowable A)
Number of subjects: 80
Study 17432401 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (flowable B)
Number of subjects: 80
Study 15112862 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Penopril)
Number of subjects: 24
Study 11453894 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified prescriptions
Number of subjects: 2014
Study 11453894 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription only medicines (POM)
Number of subjects: 2014
Study 11453894 — intervention group
Group type: EXPERIMENTAL
Intervention: POM prescriptions for patients aged 40-65 years
Number of subjects: 2014
Study 11453894 — intervention group
Group type: EXPERIMENTAL
Intervention: POM modifications in respiratory domain
Number of subjects: 2014
Study 11453894 — intervention group
Group type: EXPERIMENTAL
Intervention: POM modifications in nervous system
Number of subjects: 2014
Study 11453894 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-printed prescriptions
Number of subjects: 2014
Study 11453894 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptions by specialists
Number of subjects: 2014
Study 11453894 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptions by other GP's
Number of subjects: 2014
Study 11453894 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptions by other prescribers (dentists, midwives)
Number of subjects: 2014
Study 11453894 — intervention group
Group type: EXPERIMENTAL
Intervention: GP without online access to pharmacy computer
Number of subjects: 2014
Study 11453894 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-printed prescriptions (multivariate analysis)
Number of subjects: 2014
Study 11453894 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall correction of prescriptions in Dutch community pharmacies
Number of subjects: 2014
Study 9550954 — intervention group
Group type: COMPARATOR
Intervention: Day care
Number of subjects: 118
Study 9550954 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 118
Study 7996373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg nebulized furosemide per kg
Number of subjects: 8
Study 7996373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg nebulized furosemide per kg
Number of subjects: 8
Study 7996373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg nebulized furosemide per kg
Number of subjects: 8
Study 7996373 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg nebulized furosemide per kg
Number of subjects: 8
Study 3292038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoccult II fecal occult blood testing (rehydrated)
Number of subjects: 27700
Study 3292038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoccult II fecal occult blood testing (unhydrated)
Number of subjects: 27700
Study 3292038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoccult II fecal occult blood testing (test group)
Number of subjects: 27700
Study 3292038 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27700
Study 3292038 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group
Number of subjects: 27700
Study 31554450 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (prelistening phase and listening sessions during 4 nonstress tests)
Number of subjects: 30
Study 31554450 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (listening sessions during 4 nonstress tests)
Number of subjects: 30
Study 31554450 — intervention group
Group type: COMPARATOR
Intervention: Group C (4 nonstress tests without any listening)
Number of subjects: 30
Study 31769342 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal program for enhancing role modelling (3 months of onsite and online sessions)
Number of subjects: 18
Study 31769342 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 31308252 — intervention group
Group type: EXPERIMENTAL
Intervention: SPEA (Small-protein Enrichment Assay)
Number of subjects: 0
Study 31308252 — intervention group
Group type: EXPERIMENTAL
Intervention: SPEA
Number of subjects: 0
Study 28161828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cover group (I‐ILM folded upside‐down over the MH as a single layer)
Number of subjects: 27
Study 28161828 — intervention group
Group type: COMPARATOR
Intervention: Fill group (I‐ILM folded within the MH in multiple layers)
Number of subjects: 27
Study 28161828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cover group
Number of subjects: 27
Study 28161828 — intervention group
Group type: COMPARATOR
Intervention: Fill group
Number of subjects: 27
Study 28161828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cover group (MH over 700 µm)
Number of subjects: 27
Study 28161828 — intervention group
Group type: COMPARATOR
Intervention: Fill group (MH over 700 µm)
Number of subjects: 27
Study 26026638 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (four cycles of five minutes of cuff-induced arm ischemia with three minutes of reperfusion applied 40 minutes before CECT)
Number of subjects: 0
Study 26026638 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 22918704 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (gel) for 6 months
Number of subjects: 38
Study 21193191 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhexil
Number of subjects: 32
Study 21193191 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 32
Study 18295761 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour preincubation
Number of subjects: 0
Study 18295761 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour preincubation
Number of subjects: 0
Study 18295761 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hour preincubation
Number of subjects: 0
Study 16873324 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilizing splints (SS)
Number of subjects: 72
Study 16873324 — intervention group
Group type: COMPARATOR
Intervention: Nonoccluding control splints (CS)
Number of subjects: 72
Study 12640508 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin
Number of subjects: 12
Study 12640508 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 12
Study 12640508 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin + enalapril
Number of subjects: 12
Study 12640508 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 10701660 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 14
Study 10701660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9117181 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy at Vichy (France) for 3 weeks
Number of subjects: 188
Study 9117181 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy (control group)
Number of subjects: 188
Study 8439642 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium polycarbophil (6 g/day)
Number of subjects: 23
Study 8439642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3704978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline started 30 minutes before exercise and continued throughout the 60 minute recovery period
Number of subjects: 5
Study 3704978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline started immediately after the end of exercise
Number of subjects: 5
Study 3704978 — intervention group
Group type: COMPARATOR
Intervention: Fatiguing exercise without aminophylline
Number of subjects: 5
Study 31324081 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin-Metformin
Number of subjects: 215
Study 31324081 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride-Metformin
Number of subjects: 215
Study 30263304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GABA administration
Number of subjects: 0
Study 30263304 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 25801797 — intervention group
Group type: EXPERIMENTAL
Intervention: Velaglucerase alfa intravenous infusions at 60 U/kg every other week for 1.2-4.8 years
Number of subjects: 57
Study 25801797 — intervention group
Group type: EXPERIMENTAL
Intervention: Velaglucerase alfa intravenous infusions
Number of subjects: 57
Study 23801602 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir 750 mg every 8 hours for 15 days (T)
Number of subjects: 24
Study 23801602 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir in combination with pegylated interferon alfa-2a and ribavirin for 15 days (TPR)
Number of subjects: 24
Study 23801602 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFN/RBV plus placebo for 15 days (PR)
Number of subjects: 24
Study 20585222 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation and music (RM)
Number of subjects: 517
Study 20585222 — intervention group
Group type: COMPARATOR
Intervention: Patient teaching (PT)
Number of subjects: 517
Study 18191342 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal electrocardiogram (STAN) added to continuous FHR monitoring
Number of subjects: 0
Study 18191342 — intervention group
Group type: COMPARATOR
Intervention: Continuous FHR monitoring with fetal scalp pH testing
Number of subjects: 0
Study 18191342 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal oxymetry
Number of subjects: 0
Study 16830214 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT diet (immunonutrition)
Number of subjects: 60
Study 16830214 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (control diet)
Number of subjects: 60
Study 12967863 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% + brimonidine 0.2%
Number of subjects: 32
Study 12967863 — intervention group
Group type: COMPARATOR
Intervention: latanoprost 0.005% + placebo
Number of subjects: 32
Study 10911670 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training modules
Number of subjects: 42
Study 10911670 — intervention group
Group type: COMPARATOR
Intervention: ACT program
Number of subjects: 42
Study 8833716 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric total work
Number of subjects: 9
Study 8833716 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric relative endurance
Number of subjects: 9
Study 1350696 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg in three doses)
Number of subjects: 20
Study 1350696 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg in three doses)
Number of subjects: 20
Study 1350696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6610024 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation at various repetition rates (1.0, 3.9, 7.8, 15.5, 33.1, and 61 Hz)
Number of subjects: 9
Study 6610024 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation
Number of subjects: 9
Study 6610024 — intervention group
Group type: COMPARATOR
Intervention: Visual deprivation
Number of subjects: 9
Study 30425180 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 395
Study 30425180 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX
Number of subjects: 395
Study 28933611 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-frequency (MG: 40Hz x 360s)
Number of subjects: 80
Study 28933611 — intervention group
Group type: COMPARATOR
Intervention: Control (CG: no extra training)
Number of subjects: 80
Study 27488192 — intervention group
Group type: EXPERIMENTAL
Intervention: l-mequitazine 2.5 mg
Number of subjects: 25
Study 27488192 — intervention group
Group type: EXPERIMENTAL
Intervention: l-mequitazine 5.0 mg
Number of subjects: 25
Study 27488192 — intervention group
Group type: EXPERIMENTAL
Intervention: l-mequitazine 10 mg
Number of subjects: 25
Study 27488192 — intervention group
Group type: EXPERIMENTAL
Intervention: mequitazine 10 mg
Number of subjects: 25
Study 27488192 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 25
Study 27488192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 25056655 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt containing polydextrose, L. acidophilus NCFM, and B. lactis HN019 (Treatment Group)
Number of subjects: 0
Study 25056655 — intervention group
Group type: COMPARATOR
Intervention: Unflavored yogurt (Control Group)
Number of subjects: 0
Study 21647623 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored lifestyle intervention (Health is Wealth)
Number of subjects: 40
Study 21647623 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 40
Study 19181414 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural medicine intervention
Number of subjects: 94
Study 17440276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium 0.1% eye drops (group A)
Number of subjects: 22
Study 17440276 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops (normal saline; group B)
Number of subjects: 22
Study 15862408 — intervention group
Group type: COMPARATOR
Intervention: 300 mg clopidogrel loading dose
Number of subjects: 190
Study 15862408 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose
Number of subjects: 190
Study 16897237 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol 0.2 mg x kg(‐1)
Number of subjects: 14
Study 16897237 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol 0.1 mg x kg(‐1)
Number of subjects: 14
Study 16897237 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study 10586347 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (150 units)
Number of subjects: 21
Study 10586347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10586347 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Number of subjects: 21
Study 10586347 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 21
Study 8560679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (50 mg once daily) plus LHRH analogue (goserelin acetate 3.6 mg every 28 days or leuprolide acetate 7.5 mg every 28 days)
Number of subjects: 813
Study 8560679 — intervention group
Group type: COMPARATOR
Intervention: Flutamide (250 mg three times daily) plus LHRH analogue (goserelin acetate 3.6 mg every 28 days or leuprolide acetate 7.5 mg every 28 days)
Number of subjects: 813
Study 8560679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (50 mg once daily)
Number of subjects: 813
Study 8560679 — intervention group
Group type: COMPARATOR
Intervention: Flutamide (250 mg three times daily)
Number of subjects: 813
Study 1991673 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 13
Study 1991673 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 13
Study 1991673 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (twice daily for 2 months)
Number of subjects: 13
Study 1991673 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (1 year follow-up)
Number of subjects: 13
Study 6641302 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 15
Study 6641302 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 15
Study 6641302 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of theophylline and terbutaline
Number of subjects: 15
Study 6641302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31053180 — intervention group
Group type: EXPERIMENTAL
Intervention: GSP301 (olopatadine 665 μg and mometasone 25 μg)
Number of subjects: 1180
Study 31053180 — intervention group
Group type: EXPERIMENTAL
Intervention: GSP301
Number of subjects: 1180
Study 31053180 — intervention group
Group type: COMPARATOR
Intervention: Olopatadine (665 μg)
Number of subjects: 1180
Study 31053180 — intervention group
Group type: COMPARATOR
Intervention: Mometasone (25 μg)
Number of subjects: 1180
Study 31053180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1180
Study 29522523 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural Response System (RRS) intervention
Number of subjects: 2126
Study 25487857 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcissistic leadership qualities in unacquainted groups (Study 1)
Number of subjects: 264
Study 25487857 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcissistic leadership qualities in acquainted groups (Study 2)
Number of subjects: 264
Study 25487857 — intervention group
Group type: EXPERIMENTAL
Intervention: Transformational leadership mediation in Study 1
Number of subjects: 264
Study 25487857 — intervention group
Group type: EXPERIMENTAL
Intervention: Transformational leadership mediation in Study 2
Number of subjects: 264
Study 24556512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-sheath block (n=16)
Number of subjects: 34
Study 24556512 — intervention group
Group type: COMPARATOR
Intervention: Peri-sheath block (n=18)
Number of subjects: 34
Study 22737864 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger neo-minophagen C 100 mL dissolved in 10% dextrose 250 ml once a day intravenously, combined with decoction of turtle shell for anti-fibrosis one powder daily
Number of subjects: 94
Study 22737864 — intervention group
Group type: COMPARATOR
Intervention: Stronger neo-minophagen C alone
Number of subjects: 94
Study 19940840 — intervention group
Group type: EXPERIMENTAL
Intervention: HB‐AS02 (three doses at 0, 1, and 6 months)
Number of subjects: 151
Study 19940840 — intervention group
Group type: COMPARATOR
Intervention: HB‐AS04 (four doses at 0, 1, 2, and 6 months)
Number of subjects: 151
Study 19940840 — intervention group
Group type: EXPERIMENTAL
Intervention: HB‐AS02
Number of subjects: 151
Study 19940840 — intervention group
Group type: COMPARATOR
Intervention: HB‐AS04
Number of subjects: 151
Study 17973175 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry-generated audit, feedback, and patient reminder intervention
Number of subjects: 483
Study 17973175 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic education
Number of subjects: 483
Study 16014597 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 102
Study 16014597 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 102
Study 12406033 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide/metformin 2.5 mg/500 mg
Number of subjects: 639
Study 12406033 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide/metformin 5 mg/500 mg
Number of subjects: 639
Study 12406033 — intervention group
Group type: COMPARATOR
Intervention: Glyburide 10 mg b.i.d.
Number of subjects: 639
Study 12406033 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg
Number of subjects: 639
Study 9925692 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered Nurses
Number of subjects: 0
Study 9925692 — intervention group
Group type: EXPERIMENTAL
Intervention: General Surgeons
Number of subjects: 0
Study 9925692 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroenterology Fellows
Number of subjects: 0
Study 9925692 — intervention group
Group type: COMPARATOR
Intervention: All Providers
Number of subjects: 0
Study 7779234 — intervention group
Group type: EXPERIMENTAL
Intervention: anatomically contoured mattress overlay
Number of subjects: 17
Study 7779234 — intervention group
Group type: COMPARATOR
Intervention: standard hospital mattress
Number of subjects: 17
Study 31243920 — intervention group
Group type: EXPERIMENTAL
Intervention: Anular closure device
Number of subjects: 50
Study 28653583 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-humidified (WH) CO2 (36.7°C, 95% humidity)
Number of subjects: 101
Study 28653583 — intervention group
Group type: COMPARATOR
Intervention: Cold-dry (CD) CO2 (room temperature, 0% humidity)
Number of subjects: 101
Study 25850089 — intervention group
Group type: EXPERIMENTAL
Intervention: WALKBOT-assisted locomotor training (WLT)
Number of subjects: 30
Study 25850089 — intervention group
Group type: COMPARATOR
Intervention: Conventional locomotor training (CLT)
Number of subjects: 30
Study 23023529 — intervention group
Group type: EXPERIMENTAL
Intervention: 2RT laser therapy
Number of subjects: 23
Study 20136757 — intervention group
Group type: EXPERIMENTAL
Intervention: LIRE (six sets at 40% one repetition maximum)
Number of subjects: 23
Study 20136757 — intervention group
Group type: EXPERIMENTAL
Intervention: LIRE with VO
Number of subjects: 23
Study 20136757 — intervention group
Group type: COMPARATOR
Intervention: Seated control (CON)
Number of subjects: 23
Study 17569256 — intervention group
Group type: COMPARATOR
Intervention: HER-2/neu over-expression in androgen dependent prostate cancer (10%)
Number of subjects: 54